| 1 |
32391926 | Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells. | 2022 Jan |
4 |
| 2 |
35111229 | Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling. | 2022 |
1 |
| 3 |
35244188 | DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. | 2022 Apr |
1 |
| 4 |
35359392 | Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma. | 2022 |
2 |
| 5 |
32510618 | The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma. | 2021 Jan |
2 |
| 6 |
33015852 | Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. | 2021 Aug |
7 |
| 7 |
33517269 | Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells. | 2021 Feb |
1 |
| 8 |
33667419 | Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. | 2021 Jun |
1 |
| 9 |
33735117 | Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells. | 2021 Aug 1 |
1 |
| 10 |
33776476 | Erratum: Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]. | 2021 |
1 |
| 11 |
33951569 | Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. | 2021 Jun |
1 |
| 12 |
33987439 | BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. | 2021 |
3 |
| 13 |
34026624 | Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer. | 2021 |
1 |
| 14 |
34030133 | NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway. | 2021 May 24 |
1 |
| 15 |
34076140 | MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. | 2021 |
2 |
| 16 |
34366628 | Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. | 2021 Jul 28 |
3 |
| 17 |
34377232 | Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. | 2021 |
3 |
| 18 |
34445279 | Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. | 2021 Aug 9 |
1 |
| 19 |
34632072 | Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma. | 2021 |
1 |
| 20 |
34725436 | EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. | 2021 Nov 1 |
1 |
| 21 |
34765572 | CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. | 2021 |
2 |
| 22 |
34768109 | ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. | 2021 Dec |
1 |
| 23 |
34852817 | Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. | 2021 Dec 1 |
1 |
| 24 |
34916846 | Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway [Retraction]. | 2021 |
1 |
| 25 |
34950583 | SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. | 2021 |
4 |
| 26 |
32203105 | Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. | 2020 Mar |
1 |
| 27 |
32461380 | LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. | 2020 May 26 |
1 |
| 28 |
32504550 | Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 Aug |
1 |
| 29 |
32606928 | Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway. | 2020 |
1 |
| 30 |
32970612 | GHR knockdown enhances the sensitivity of HCC cells to sorafenib. | 2020 Sep 24 |
1 |
| 31 |
32982405 | Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway. | 2020 |
1 |
| 32 |
33051131 | Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells. | 2020 Dec |
7 |
| 33 |
33097691 | The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. | 2020 Oct 23 |
1 |
| 34 |
33112540 | Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro. | 2020 Oct 1 |
2 |
| 35 |
33163195 | Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. | 2020 Oct |
1 |
| 36 |
33379356 | Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. | 2020 Dec 28 |
2 |
| 37 |
30142009 | Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. | 2019 |
2 |
| 38 |
30456603 | The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. | 2019 Oct |
3 |
| 39 |
30663411 | Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway. | 2019 Dec |
2 |
| 40 |
30975543 | Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly. | 2019 May |
1 |
| 41 |
31053148 | LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. | 2019 May 3 |
7 |
| 42 |
31233189 | Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells. | 2019 Aug |
3 |
| 43 |
31233204 | Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway. | 2019 Sep |
3 |
| 44 |
31385002 | Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. | 2019 Oct |
2 |
| 45 |
31387809 | Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. | 2019 Oct |
1 |
| 46 |
31417635 | KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. | 2019 |
1 |
| 47 |
31439713 | Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment. | 2019 Nov |
1 |
| 48 |
31698564 | Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. | 2019 Jul 8 |
2 |
| 49 |
29156516 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. | 2018 Jan |
5 |
| 50 |
29207150 | Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer. | 2018 Feb |
2 |